# Biogen (BIIB) — Analyst Forecast

BIIB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/biib/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 25 | 11 | 1 | 37 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $175.00 | $241.69 | $300.00 | 16 |

Last price $235.35 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | JP Morgan | Upgraded | Neutral → Overweight | $300.00 |
| Oct 9, 2026 | UBS | Maintained | Buy | $270.00 |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | $256.00 |
| Sep 10, 2026 | HSBC | Maintained | Reduce | $175.00 |
| Sep 3, 2026 | Piper Sandler | Maintained | Overweight | $245.00 |
| Aug 25, 2026 | RBC Capital | Maintained | Outperform | $260.00 |
| Aug 13, 2026 | Wolfe Research | Upgraded | Peer Perform → Outperform | $300.00 |
| Aug 4, 2026 | Mizuho | Maintained | Outperform | $241.00 |
| Aug 3, 2026 | Citigroup | Maintained | Neutral | $215.00 |
| Jul 30, 2026 | Wedbush | Maintained | Neutral | $215.00 |
| Jul 30, 2026 | Canaccord Genuity | Maintained | Buy | $248.00 |
| Jul 30, 2026 | TD Cowen | Maintained | Buy | $225.00 |
| Jul 30, 2026 | RBC Capital | Maintained | Outperform | $240.00 |
| Jul 30, 2026 | Morgan Stanley | Maintained | Equal-Weight | $231.00 |
| Jul 30, 2026 | HC Wainwright & Co. | Maintained | Buy | $251.00 |
| Jul 30, 2026 | UBS | Maintained | Buy | $240.00 |
| Jul 29, 2026 | Barclays | Maintained | Equal-Weight | $200.00 |
| Jul 21, 2026 | B of A Securities | Maintained | Neutral | $215.00 |
| Jul 21, 2026 | Guggenheim | Maintained | Buy | $280.00 |
| Jul 13, 2026 | Truist Securities | Upgraded | Hold → Buy | $235.00 |

## Frequently Asked Questions

### What is the price target for BIIB stock?

The average 12-month analyst price target for Biogen (BIIB) is $241.69, with a high estimate of $300.00 and a low of $175.00, across 16 analysts.

### Is BIIB a buy, sell, or hold?

Analysts covering Biogen currently average a Buy rating: 25 buy, 11 hold and 1 sell, from 37 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for BIIB?

The average price target of $241.69 implies 2.69% upside from the last price of $235.35.

### What is the latest analyst rating on BIIB?

On Oct 12, 2026, JP Morgan upgraded Biogen to Overweight with a price target of $300.00.

## Similar Stocks

- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [IONS](https://www.lighthorse.io/tickers/ions) — Ionis Pharmaceuticals, Inc. - Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [PRTA](https://www.lighthorse.io/tickers/prta) — Prothena Corporation plc - Ordinary Shares
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).